Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available Literature

Apremilast, an oral phosphodiesterase-4 inhibitor, has been used for 22 non-FDA-approved dermatological indications, showing varied efficacy. The best evidence supports its use in Atopic Dermatitis, Alopecia Areata, and Hidradenitis Suppurativa, with randomized controlled trials. Other conditions like Cutaneous Sarcoidosis, Lichen Planus, Rosacea, and Vitiligo have been studied in prospective open-label trials, while individual case reports cover a range of other dermatoses. Despite its better safety profile and tolerability over conventional immunosuppressants, more controlled, randomized studies with adequate sample sizes are needed for comprehensive analysis.